Financial Relationships With Ineligible Companies

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as "commercial interests") within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients." Below are the financial interests that faculty members of this course have had within the past 24 months. View the Faculty Financial Disclosure Policy.

Medical Management of People With HIV as They Age: A Course for Non-Geriatricians

December 2, 2025

Course Presenters and Panelists	
Anna E. Coghill, PhD, MPH Associate Member H. Lee Moffitt Cancer Center & Research Institute Tampa, FL	Dr Coghill reported no relevant financial relationships with ineligible companies. (Updated November 10, 2025)
Michael J. Corley, MA, PhD Associate Professor University of California San Diego La Jolla, CA	Dr Corley reported serving as a scientific advisor to TruDiagnostic. (Updated November 8, 2025)
Shelli Farhadian, MD, PhD Associate Professor of Medicine Yale School of Medicine New Haven, CT	Dr Farhadian reported no relevant financial relationships with ineligible companies. (Updated November 10, 2025)
Chris Longenecker, MD Professor of Medicine University of Washington Seattle, WA	Dr Longenecker reported serving as an advisor to Gilead Sciences, Inc. (Updated November 10, 2025)
David H. Spach, MD Editor-in-Chief, National HIV Curriculum Professor of Medicine University of Washington Seattle, WA	Dr Spach reported no relevant financial relationships with ineligible companies. (Updated November 10, 2025)

IAS–USA CME Planners and Reviewers	
Roger J. Bedimo, MD, MS Professor of Medicine University of Texas Southwestern Medical Center Dallas, TX	Dr Bedimo reported receiving research grants awarded to his institution from Merck & Co, Inc, and serving on the scientific advisory boards for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, Shionogi, and Janssen Pharmaceuticals. (Updated November 8, 2025)
Kristine M. Erlandson, MD, MS Professor of Medicine University of Colorado Aurora, CO	Dr Erlandson reported serving on advisory boards for Merck & Co, Inc, ViiV Heathcare, and Gilead Sciences, Inc, and provision of study drug from Theratechnologies, Inc. (Updated November 8, 2025)
Donna M. Jacobsen Executive Director/President IAS–USA San Francisco, CA	Ms Jacobsen reported no relevant financial relationships with ineligible companies. (Updated November 10, 2025)

IAS–USA Boards
The nonstaff members of the IAS–USA Scientific Advisory Board and Governance Board are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.